Antidepressants, Emotions and Personality
Launched by UNIVERSITY OF OXFORD · Sep 16, 2013
Trial Information
Current as of May 14, 2025
Completed
Keywords
ClinConnect Summary
Forty healthy volunteers with high scores on the Eysenck Personality Questionnaire Neuroticism scale will be recruited from the general population using posters and advertising in local newspapers and on internet. All advertisement will direct volunteers to a specific website (http://weblearn.ox.ac.uk/site/users/psyc0390/public/) (hosted in the Weblearn area of the University of Oxford) that will report the study Information Sheet. People clicking on the "I agree to participate" link will then be able to leave their contact details and fill in a shortened version of the Eysenck Personality ...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Participant is willing and able to give informed consent for participation in the study.
- • Male or Female, aged 18 - 50 years
- • Eysenck Personality Questionnaire Neuroticism scale ≥15/24
- • Fluent in English language (in order to understand all study instructions and tasks using verbal stimuli)
- Exclusion Criteria:
- • any significant medical condition
- • current or past history of psychiatric disorder
- • family history of mania
- • pregnancy or breastfeeding
- • taking any current medication (except the contraceptive pill)
- • having taken part in other trials involving psychotropic drug intake in the previous three months
About University Of Oxford
The University of Oxford, a prestigious institution renowned for its excellence in research and education, serves as a leading clinical trial sponsor dedicated to advancing medical science and improving patient care. With a rich history of innovation and a multidisciplinary approach, the university leverages its extensive expertise in various fields, including medicine, public health, and biomedical research, to conduct rigorous clinical trials. Collaborating with healthcare professionals, industry partners, and regulatory bodies, the University of Oxford aims to translate groundbreaking research findings into effective therapies and interventions, contributing to the global effort of enhancing health outcomes.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Oxford, Oxfordshire, United Kingdom
Patients applied
Trial Officials
Martina Di Simplicio, MD
Principal Investigator
University of Oxford (at the time of study); MRC Cognition and Brain Sciences unit (current)
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials